Search results
Results from the WOW.Com Content Network
Chronic hepatitis C is defined as infection with the hepatitis C virus persisting for more than six months based on the presence of its RNA. [18] Chronic infections are typically asymptomatic during the first few decades, [ 18 ] and thus are most commonly discovered following the investigation of elevated liver enzyme levels or during a routine ...
The hepatitis C virus (HCV) [3] is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer ( hepatocellular carcinoma , abbreviated HCC) and lymphomas in humans.
“With treatment, almost 100 percent of people can be free of hepatitis C,” says Dr. Menon. The exact treatment you receive will depend on factors including the amount of virus in your body ...
Hepatitis A and hepatitis B can be prevented by vaccination. Effective treatments for hepatitis C are available but costly. [6] In 2013, about 1.5 million people died from viral hepatitis, most commonly due to hepatitis B and C. [6] East Asia, in particular Mongolia, is the region most affected. [6]
Download as PDF; Printable version; A Hepatitis Testing Day event in 2016. Hepatitis Testing Day is May 19 in the United States. References. This page was last edited ...
Advocates say as many as 3.9 million people are living with chronic hepatitis C. Now doctors are using a new method to treat mothers before they pass the virus down to their children.
World Hepatitis Day provides an opportunity to focus on actions such as: [1] Raising awareness of the different forms of hepatitis and how they are transmitted; Strengthening prevention, screening and control of viral hepatitis and its related diseases; Increasing hepatitis B vaccine coverage and integration into national immunization ...
Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. [8] It is a fixed-dose combination of ledipasvir and sofosbuvir. [8] Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. [9] Some evidence also supports use in HCV genotype 3 and 4. [9]